Opinion

Video

Addressing Potential Barriers to the Adoption of Afami-Cel Therapy

A panelist discusses how key barriers to broad afamitresgene autoleucel (afami-cel) adoption include manufacturing turnaround times, the need for specialized cell therapy centers, testing requirements, and coordination of lymphodepletion timing, though these challenges are being actively addressed through improved processes and infrastructure development.

Video Player is loading.
Current Time 0:00
Duration 4:19
Loaded: 0%
Stream Type LIVE
Remaining Time 4:19
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Video content above is prompted by the following:

  • What are the logistical or clinical barriers for broad adoption of afami-cel?